# Luvelta PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/luvelta

> Luvelta, sponsored by SUTRO BIOPHARMA, INC. (STRO): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | luvelta |
| Codes |  |
| Sponsor | SUTRO BIOPHARMA, INC. (STRO) https://sec-api.dev/companies/stro/catalysts |
| Indications | platinum-resistant ovarian cancer in june 2023, frα-expressing non-small cell lung cancer, or nsclc, with luvelta |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Jun 2023: trial start

- Status: completed. Date confidence: month. Stage: 2/3. Indication: platinum-resistant ovarian cancer in June 2023.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0000950170-24-126407): "Following the studies discussed above, we initiated a Phase 2/3 study, the REFRαME-O1 study, of luvelta for the treatment of platinum-resistant ovarian cancer in June 2023." https://www.sec.gov/Archives/edgar/data/1382101/000095017024126407/stro-20240930.htm

### Aug 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: FRα-expressing non-small cell lung cancer, or NSCLC, with luvelta.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0000950170-24-126407): "Our IND for the treatment of FRα-expressing non-small cell lung cancer, or NSCLC, with luvelta was cleared by the FDA in the first half of 2024 and we initiated the Phase 2 study in August 2024." https://www.sec.gov/Archives/edgar/data/1382101/000095017024126407/stro-20240930.htm

### 2025: interim data readout

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126382): "A Phase 2 trial for the treatment of NSCLC is underway, with initial data expected in 2025." https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/stro-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/luvelta.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Luvelta PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/luvelta

```bibtex
@misc{secapidev_pdufa_luvelta_20261116,
  title        = {Luvelta PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/luvelta}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_luvelta_20261116","title":"Luvelta PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/luvelta","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
